Executive Management

Christine Lind
CEO

Employed: 2024

Born: 1974

Education: Bachelor of Science in Finance and Information Systems, New York University, Stern School of Business. Masters in Business Administration in Finance and Management, Columbia Business School.

Previous assignments: Management roles in the life sciences industry, including VP Business Development at LifeCell Corporation, EVP Business Development and subsequently CEO of Medivir AB, Strategic Advisor to BioArctic AB, and most recently, SVP Corporate Development for SSI Strategy. Chairman of the Board, Mendus AB. Prior to that, as a strategic and financial advisor to biotech and pharmaceutical companies (at Merrill Lynch & Co).

Other assignments: Member of the Board, Xspray Pharma AB. Chairman and CEO, Lind Growth Strategy AB.

Shareholdings: 85,000 B-shares as a personal holding
Patrick Bach
CFO

Employed: 2023

Born: 1983

Education: MSc in Finance and Strategic Management from Copenhagen Business School with graduating MSc courses at Columbia Business School, Harvard University, and The London School of Economics and Political Science. BSc in Economics and Business Administration from Copenhagen Business School.

Previous assignments: Various managerial positions at Atos Medical AB, most recently Managing Director Nordics and Vice President Consumer. Prior to that, several managerial positions at Coloplast, including Head of Strategy Wound Care, and Associate at McKinsey & Company as well as a Business Analyst at Novo Nordisk A/S.
Nina Nornholm
Head of Corporate Communication & Investor Relations

Employed: 2023

Born: 1967

Education: Studies in Business Administration (Marketing and Communication) at Stockholm University.

Previous assignments: More than 25 years of experience in the global financial industry with focus on strategic communication, branding, and investor relations. Head of Communications at private equity firm EQT 2007-2022. Prior to that, communication specialist roles at SEB Asset Management and investment bank Alfred Berg.

Other assignments: Board member Plan International Sweden.

Shareholdings: 36,023 call options.
Mikael Sander
COO

Employed: 2023

Born: 1959

Education: Master of Science in Business & Economics, University of Gothenburg and MBA, University of Lund, Sweden.

Previous assignments: Managerial positions at Dentsply Sirona (responsible for global digital implants business, global commercial and business Europe, North American and Asia, VP Sales, General Manager in Boston, and VP of Business Development in Mölndal, Sweden). Prior to that, commercial and management roles in operations, finance, and business development at Astra Zeneca and Astra Tech.

Other assignments: Board member Corticalis AS and Mevia AB.

Shareholdings: 10,868 B-shares as a personal holding and 288,182 call options.
Nathaniel Bachrach
Interim Head of R&D

Born: 1966

Education: Doctor of Philosophy (Ph.D.) in Mechanical Engineering from Columbia University. Master and Bachelor of Science, Mechanical Engineeringat at Columbia University. Bachelor of Science, Physics at Yeshiva University.

Previous assignments:  25+ years of experience developing products for global commercialization in plastic reconstructive and general surgery, orthopaedics, and periodontics. Previous assignments were Executive Vice President and Chief Scientific Officer at 3DBio Corporation and Vice President Research & Technology at LifeCell Corporation. Prior to that various leadership and technical roles within LifeCell and Organigenesis Inc. He also has extensive experience and an impressive record of publications and innovative patents within Bactiguard’s strategic therapeutic areas.

Other assignments:  Consulting EVP, Strategy, Science & Product

Christine Lind

Patrick Bach

Nina Nornholm

Mikael Sander

Nathaniel Bachrach